{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:38:21Z","timestamp":1787164701875,"version":"build-2736575974"},"reference-count":15,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Laryngoscope"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The randomized, double\u2010blind, placebo\u2010controlled LIBERTY SINUS\u201024 and SINUS\u201052 studies demonstrated that dupilumab is effective for chronic rhinosinusitis with nasal polyps (CRSwNP) when used with an intranasal corticosteroid (INCS); however, INCSs are not approved for CRSwNP in Japan. The current study aimed to investigate the effectiveness and safety of dupilumab monotherapy in Japanese individuals with CRSwNP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This phase 4, open\u2010label, single\u2010arm, multicenter study enrolled adult individuals with CRSwNP inadequately controlled with standard care therapies, including systemic corticosteroids and\/or surgery. Subcutaneous dupilumab 300\u2009mg was administered every 2\u2009weeks; in participants with stable disease at week 24 (improvement of \u2265\u20092 points in the Nasal Polyp Score [NPS] from baseline at weeks 16 and 24), the dosing interval could be modified to every 4\u2009weeks. The primary endpoint was the proportion of responders at week 24.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study included 25 individuals with CRSwNP (mean\u2009\u00b1\u2009standard deviation age of 53.4\u2009\u00b1\u200913.6\u2009years; 60.0% male). At week 24, 23 participants (92.0%) were considered responders to dupilumab. Reductions from baseline to week 24 in bilateral endoscopic NPS (mean change \u22122.4), nasal congestion severity score (\u22121.58), and Lund\u2010Mackay scores (\u22125.6) were observed with dupilumab. Dupilumab was well tolerated; over 52\u2009weeks, 16 participants (69.6%) experienced a treatment\u2010emergent adverse event (TEAE). Most TEAEs were mild in severity; moderate and severe TEAEs were reported in five (21.7%) and one (4.3%) participant, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Dupilumab monotherapy was effective and well tolerated in Japanese individuals with symptomatic CRSwNP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Level of Evidence<\/jats:title>\n                    <jats:p>3.<\/jats:p>\n                    <jats:p>\n                      <jats:bold>Trial Registration:<\/jats:bold>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      identifier: NCT05049122.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/lary.70037","type":"journal-article","created":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T10:14:41Z","timestamp":1756548881000},"page":"4625-4632","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effectiveness and Safety of Dupilumab Monotherapy in Japanese Patients With Chronic Rhinosinusitis With Nasal Polyps"],"prefix":"10.1002","volume":"135","author":[{"given":"Shigeharu","family":"Fujieda","sequence":"first","affiliation":[{"name":"Department of Otorhinolaryngology\u2010Head and Neck Surgery, Faculty of Medical Sciences University of Fukui  Fukui Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0012-149X","authenticated-orcid":false,"given":"Tetsuji","family":"Takabayashi","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology\u2010Head and Neck Surgery, Faculty of Medical Sciences University of Fukui  Fukui Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2821-6976","authenticated-orcid":false,"given":"Nobuo","family":"Ohta","sequence":"additional","affiliation":[{"name":"Division of Otolaryngology Tohoku Medical and Pharmaceutical University  Sendai Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamoru","family":"Yoshikawa","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology Toho University Ohashi Medical Center  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kibe","sequence":"additional","affiliation":[{"name":"Sanofi K.K  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Ishida","sequence":"additional","affiliation":[{"name":"Sanofi K.K  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhisa","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Sanofi K.K  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Sanofi K.K  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Amin","sequence":"additional","affiliation":[{"name":"Clinical Sciences, Immunology and Inflammation, Regeneron Pharmaceuticals, Inc.  Tarrytown New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakiea","family":"Wright","sequence":"additional","affiliation":[{"name":"Sanofi  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lacey","family":"Robinson","sequence":"additional","affiliation":[{"name":"Sanofi  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Yahata","sequence":"additional","affiliation":[{"name":"Sanofi K.K  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,8,30]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-015-0540-2"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2019.12.021"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-052016-100401"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2019.05.009"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2016.04.012"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2008.01828.x"},{"key":"e_1_2_9_8_1","first-page":"343","article-title":"The GALEN Rhinosinusitis Cohort: Chronic Rhinosinusitis With Nasal Polyps Affects Health\u2010Related Quality of Life","volume":"57","author":"Khan A.","year":"2019","journal-title":"Rhinology"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2019.07.002"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.12644"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/1945892418814768"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-012-0247-6"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.01.020"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.14151"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31881-1"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.16355"}],"container-title":["The Laryngoscope"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/lary.70037","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T09:07:01Z","timestamp":1765876021000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/lary.70037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,30]]},"references-count":15,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1002\/lary.70037"],"URL":"https:\/\/doi.org\/10.1002\/lary.70037","archive":["Portico"],"relation":{},"ISSN":["0023-852X","1531-4995"],"issn-type":[{"value":"0023-852X","type":"print"},{"value":"1531-4995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,30]]},"assertion":[{"value":"2025-05-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}